S.Biomedics Co., Ltd.

S.Biomedics Co., Ltd.

KKRX:304360
17,510.00
KRW
-290.00
(-1.63%)
-875.98EPS
266.28BMarket Cap

Total Valuation

KRW

As of June 30, 2026, S.Biomedics Co., Ltd. carries a market capitalization of 266.28B, placing it among publicly traded companies globally. Its enterprise value stands at 243.79B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap266.28B
Enterprise Value243.79B

Share Statistics

As of June 30, 2026, S.Biomedics Co., Ltd. has 12.39M shares outstanding.

Shares Outstanding12.39M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 15.92, and the price-to-book ratio stands at 8.87.

PS Ratio15.92
PB Ratio8.87
P/TBV Ratio9.00
P/FCF Ratio-24.06
P/OCF Ratio-36.91

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 14.78 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 243.79B versus a market cap of 266.28B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales14.78

Financial Position

As of June 30, 2026, S.Biomedics Co., Ltd. maintains a current ratio of 6.56, meaning it holds 6.6x the short-term assets needed to cover near-term liabilities.

Current Ratio6.56
Quick Ratio5.91
Debt / Equity44.12
Debt / EBITDA-1.96

Financial Efficiency

KRW

Over the twelve months ended June 30, 2026, S.Biomedics Co., Ltd. posted a negative return on equity (ROE) of -64.15, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -20.42, reflecting losses generated across the asset base. The company generates approximately 314.14M in revenue per employee across its workforce of 52.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.92 indicates how many times S.Biomedics Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-64.15
Return on Assets (ROA)-20.42
Revenue Per Employee314.14M
Employee Count52.50
Inventory Turnover3.92

Taxes

KRW

Over the twelve months ended June 30, 2026, S.Biomedics Co., Ltd. recorded 310.17M in income tax expense. The company reported a pretax loss of -10.39B and -12.06B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax310.17M

Stock Price Statistics

KRW

As of the close on November 17, 2026, S.Biomedics Co., Ltd.'s stock has declined approximately 34.17% over the past 52 weeks. The 50-day moving average sits at 20,179.60, while the 200-day moving average is 25,870.45.

52-Week Price Change-34.17%
50-Day Moving Average20,179.60
200-Day Moving Average25,870.45

Income Statement

KRW

Over the twelve months ended June 30, 2026, S.Biomedics Co., Ltd. generated 16.49B in revenue and converted that into -12.06B in net income, yielding earnings per share of -875.98. EBITDA reached -8.87B, while operating income came in at -11.28B.

Revenue16.49B
Gross Profit8.13B
Operating Income-11.28B
Pretax Income-10.39B
Net Income-12.06B
EBITDA-8.87B
EBIT-11.28B
Earnings Per Share (EPS)-875.98

Balance Sheet

KRW

As of June 30, 2026, S.Biomedics Co., Ltd. holds 49.40B in cash and equivalents against 17.43B in total debt, resulting in a net debt position of -23.73B. Total book value stands at 30.03B, with working capital of 46.45B providing operational flexibility.

Cash & Cash Equivalents49.40B
Total Debt17.43B
Net Debt-23.73B
Equity (Book Value)30.03B
Book Value Per Share2,424.98
Working Capital46.45B

Cash Flow

KRW

S.Biomedics Co., Ltd. produced -7.11B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -3.80B in capital expenditures, free cash flow totaled -10.91B - equivalent to -893.58 per share.

Operating Cash Flow-7.11B
Capital Expenditures-3.80B
Free Cash Flow-10.91B
FCF Per Share-893.58

Margins

Over the twelve months ended June 30, 2026, S.Biomedics Co., Ltd. posted a gross margin of 49.27, reflecting its pricing power and cost economics. The operating margin of -68.42 and net profit margin of -73.11 provide insight into operational efficiency.

Gross Margin49.27
Operating Margin-68.42
Pretax Margin-62.98
Profit Margin-73.11
EBITDA Margin-53.79

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -4.16: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -14.54, meaning S.Biomedics Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-14.54
FCF Yield-4.16

Scores

As of June 30, 2026, S.Biomedics Co., Ltd. has an Altman Z-Score of 3.14, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.14